Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
Authors:
- Anton L PozniakAPAnton L Pozniak
- Margaret A JohnsonMJMargaret A Johnson
- Andreas PlettenbergAPAndreas Plettenberg
- Schlomo StaszewskiSSSchlomo Staszewski
- Andy I M HoepelmanAHAndy I M Hoepelman
- Michael S SaagMSMichael S Saag
- Frank D GoebelFGFrank D Goebel
- Jürgen K RockstrohJRJürgen K Rockstroh
- Bruce J DezubeBDBruce J Dezube
- Tim M JenkinsTJTim M Jenkins
- Christine MedhurstCMChristine Medhurst
Top Cited Papers
- 5 October 2005
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 11 (11) , 1170-1172
Abstract
We assessed the efficacy and safety of 10-d monotherapy with the orally administered CCR5 antagonist maraviroc in 63 HIV-1-positive individuals prescreened for the absence of CXCR4-using virus. Maximum reduction in viral load occurred at a median of 10-15 d, with a mean reduction of >or=1.6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach.Keywords
This publication has 13 references indexed in Scilit:
- Spirodiketopiperazine-Based CCR5 Inhibitor Which Preserves CC-Chemokine/CCR5 Interactions and Exerts Potent Activity against R5 Human Immunodeficiency Virus Type 1 In VitroJournal of Virology, 2004
- Genetic and Phenotypic Analyses of Human Immunodeficiency Virus Type 1 Escape from a Small-Molecule CCR5 InhibitorJournal of Virology, 2004
- Simpler Regimens May Enhance Adherence to Antiretrovirals in HIV-Infected PatientsHIV Research & Clinical Practice, 2002
- Inhibitory Effects of Small-Molecule CCR5 Antagonists on Human Immunodeficiency Virus Type 1 Envelope-Mediated Membrane Fusion and Viral ReplicationAntimicrobial Agents and Chemotherapy, 2001
- SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infectionin vitroandin vivoProceedings of the National Academy of Sciences, 2001
- EfavirenzDrugs, 1998
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- Early protective effect of CCR-5 Δ32 heterozygosity on HIV-1 disease progressionAIDS, 1997
- Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individualsAIDS, 1997
- Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural GeneScience, 1996